What Kalydeco Treats: Main Uses and Benefits

Kalydeco is used to manage Cystic Fibrosis (CF) in patients who possess at least one specific, responsive CFTR gene mutation, such as G551D and R117H, among others, that are relevant to the therapeutic domain. This therapy is applied in conjunction with other necessary care for managing conditions marked by specific genetic characteristics.

The medication may assist with therapeutic relief for the ongoing, burdensome respiratory manifestations of CF, including persistent thick, sticky mucus and chronic cough. The treatment is considered relevant for managing the potential functional strain on lung capacity and assists with easing the frequency of acute, disruptive pulmonary exacerbations.

Beyond the lungs, it also addresses symptoms related to systemic imbalance and other symptoms linked to organ-specific functional stress, which may contribute to improved comfort and stability in nutritional status and weight gain. This approach is considered relevant for long-term support in situations where patients experience these specific symptoms. This therapeutic support may contribute to improved comfort and stability for those living with the condition.

Quick Fact: Relief for Respiratory Strain
The treatment supports symptom management by easing the functional strain on lung capacity and is relevant for managing symptoms that interfere with daily comfort.

Regulatory References

1. Kalydeco | European Medicines Agency (EMA)

The eligibility for using Kalydeco (ivacaftor) is strictly governed by official regulatory documentation, primarily based on the patient’s genetic profile, age, and organ function status.

Contraindicated and Non-Eligible Populations

Classification	Population Restriction	Eligibility Status
Absolute Contraindication	Known hypersensitivity to ivacaftor or any of its excipients.	Prohibited
Genotype Limitation	Patients with Cystic Fibrosis who are homozygous for the F508del mutation.	Not Effective (Limitation of Use)

Age and Organ Function Restrictions

Use of Kalydeco is restricted to patients with Cystic Fibrosis who have at least one responsive CFTR gene mutation. Age eligibility generally begins as young as 1 month (U.S. label) or 4 months (other regulatory labels), though use in infants under 1 month is officially not recommended as safety has not been established.

Eligibility is conditional on liver function. The medicine is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C). For those with moderate impairment, use is permitted but requires a dose modification, as specified in the official prescribing information. Caution is also recommended for patients with severe renal impairment or end-stage renal disease. Furthermore, if liver enzymes rise significantly (e.g., ALT or AST greater than 5x the upper limit of normal), treatment must be interrupted.

The official interaction profile for Kalydeco (ivacaftor) is defined primarily by its role as a sensitive substrate and a weak inhibitor of the Cytochrome P450 3A (CYP3A) enzyme and the P-glycoprotein (P-gp) transporter, as documented in regulatory information.

Interaction Scope

Category	Description
Medicinal product categories with documented interactions	Strong and moderate CYP3A Inhibitors; Strong CYP3A Inducers; Sensitive P-gp Substrates; Sulfonylureas; Hormonal Contraceptives.
Specific interacting medicines (if explicitly listed)	Ketoconazole, Rifampin, Fluconazole, Itraconazole, Phenytoin, Carbamazepine, Digoxin.
Mechanistic basis of interactions (only if stated in label)	Ivacaftor is a sensitive substrate of CYP3A. Ivacaftor and its M1 metabolite are weak inhibitors of CYP3A and P-gp.
Population-specific interaction notes (if applicable)	Interaction effects are heightened in patients with moderate or severe hepatic impairment, which requires a lower dose of ivacaftor when co-administered with CYP3A inhibitors.
Interaction-related restrictions	Co-administration with strong CYP3A inducers (e.g., rifampin, phenytoin) and the herbal product St. John's Wort is not recommended due to a substantial decrease in ivacaftor exposure. Food or drink containing grapefruit or Seville oranges must be avoided as they may increase ivacaftor exposure.

Resulting Interaction Structure

Official interaction statements:

• Co-administration with strong CYP3A inhibitors (e.g., ketoconazole) results in a substantial increase in ivacaftor exposure.
• Co-administration with moderate CYP3A inhibitors (e.g., fluconazole) also increases ivacaftor exposure.
• Ivacaftor may increase the systemic exposure of co-administered medicines that are sensitive substrates of P-gp (e.g., digoxin) or CYP3A (e.g., midazolam).

Regulatory documents define the product's interaction structure based on ivacaftor's role as both a sensitive substrate and a weak inhibitor of the CYP3A enzyme, alongside its documented P-gp inhibition. This classification dictates all official restrictions and requirements for dose adjustment with specific medicinal product classes.

Direct CFTR Channel Potentiation

Ivacaftor acts as a CFTR potentiator, binding directly to the CFTR protein to stabilize the ion channel in its open state. This mechanism is highly specific, enhancing the channel's gating function primarily for those CFTR proteins (like Class III mutations) that are present on the cell surface but exhibit impaired opening capabilities.

Re-establishment of Epithelial Ion and Fluid Transport

The direct molecular action initiates a vital physiological cascade: The restored channel gating facilitates the transport of chloride ions ( Cl^-) out of the cell, which then creates the necessary osmotic gradient to draw water onto the epithelial surface. This effect modulates the ion and fluid transport pathway, directly modulating the cellular function associated with restricted ion movement.

Normalization of Secretion Hydration

As a direct consequence of re-established fluid transport, this mechanism supports the normalization of fluid balance across epithelial membranes in multiple organs. The resulting increased water content on the tissue surface rehydrates otherwise thick, viscous bodily secretions, contributing to the enhancement of ciliary action and the altered viscosity of exocrine secretions.

How Kalydeco (Ivacaftor) is Used

Kalydeco is administered orally as a long-term maintenance therapy, following strict, labeled instructions regarding dose, frequency, and administration context. The standard regimen for this medication is twice daily (every 12 hours).

---

Administration Details

The dosage form used depends on the patient’s age and weight, as specified by regulatory guidelines.

Patient Group	Dosing Form and Frequency
Aged 6 years	One 150 mg tablet every 12 hours.
Aged 1 month to <6 years	Oral granules (weight-based strengths from 5.8 mg to 75 mg) every 12 hours.

---

Contextual Use Requirements

Administration must be synchronized with food intake: Kalydeco must be taken with fat-containing food to ensure proper absorption.

Specific instructions govern the handling of each form:

• Tablets must be swallowed whole and should not be crushed or chewed.
• Oral granules should be mixed into 5 mL of soft food or liquid that is at or below room temperature and consumed completely within one hour.

Patients are instructed to avoid grapefruit and Seville oranges while using this medicine. If a dose is missed, it should be taken immediately only if it is within 6 hours of the scheduled time. If more than 6 hours have passed, the missed dose must be skipped, and the patient should resume the normal twice-daily schedule with the next dose. The dosage regimen requires reduction in patients with hepatic impairment or when co-administered with strong CYP3A inhibitors.

Research Evidence / Overview of Studies

Research on Mechanism and Initial Findings

Ivacaftor (Kalydeco) is a CFTR potentiator, the first of its kind to address the underlying defect in cystic fibrosis (CF) for certain mutations. Research has explored the drug's activity regarding the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, specifically examining its role in certain gating mutations (Class III). Studies have examined whether this potentiation of the protein's channel-opening function is associated with changes in symptoms.

---

Studies on Efficacy and Symptom Change

Initial randomized controlled trials (RCTs) demonstrated that for individuals with the G551D mutation, treatment with ivacaftor was associated with measurable outcomes. Follow-up studies, including open-label extension trials, have investigated the observed response over longer durations. Key areas of investigation include:

• Lung Function: Clinical trials and long-term registry analyses have evaluated changes in Forced Expiratory Volume in 1 second (% predicted FEV1). Studies reported that observed improvements in lung function, evident within the first month, were often continued over several years of treatment.
• Nutritional Status: Research has examined the effects of treatment on nutritional parameters, including improvements in Body Mass Index (BMI) and weight-for-age scores, which were observed in both pediatric and adult participants.

---

Investigating Long-Term Outcomes and Specific Populations

Real-world evidence from patient registries, combined with data from long-term extension studies, has provided insights into the duration of observed responses.

• Pulmonary Exacerbations: Registry data has evaluated whether ivacaftor treatment is associated with a reduction in the rate of pulmonary exacerbations and related hospitalizations compared to untreated patients with CF.
• Survival and Transplant: Retrospective, longitudinal studies investigating the impact over approximately eight years suggested that ivacaftor treatment was associated with a lower rate of mortality and lung transplant in the treated cohort compared to matched control groups.
• Pediatric Populations: Studies have expanded the evidence base to very young children (as young as one month) with responsive mutations, primarily focusing on safety and observable physiological markers such as sweat chloride levels.

Key Studies & References Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review

Common questions about Kalydeco (FAQ)

Q: How is Kalydeco different from older, traditional treatments for cystic fibrosis?

Official information describes Kalydeco as a CFTR potentiator that addresses the molecular cause of cystic fibrosis by improving the function of the defective protein. This action is distinct from older, traditional treatments which typically focus on managing the symptoms of the disease, such as clearing mucus or fighting infection.

Q: Can Kalydeco be used in combination with other cystic fibrosis treatments?

Regulatory documents state that Kalydeco can be used as a single medicine (monotherapy) for patients with specific responsive mutations. It is also approved for use in combination with certain other cystic fibrosis medicines that contain different active ingredients for a broader range of mutations.

Q: What is a 'responsive' CFTR mutation in the context of Kalydeco use?

The medicine is indicated for mutations that are considered responsive, which means the treatment has demonstrated effectiveness for that specific gene change. This typically includes gating mutations (Class III), where the CFTR protein is present on the cell surface but exhibits impaired opening capabilities to allow fluid transport.

Q: Why is genetic testing required before treatment with Kalydeco can begin?

According to the official product information, genetic testing is required to confirm that the patient has at least one CFTR gene mutation that is known to be responsive to Kalydeco. This step is necessary to confirm eligibility for the medicine based on the patient's specific genetic profile.

Q: Do side effects from Kalydeco, like headaches or diarrhea, usually lessen over time?

Official safety constraints note that certain effects, such as elevations in liver enzymes, are more frequently observed at the start of treatment. However, regulatory documents do not provide a general statement regarding whether common side effects like headaches or diarrhea typically lessen or resolve over time for all individuals.

Q: Is there a known link between Kalydeco and changes in blood pressure or blood sugar levels?

Official product information lists hypoglycemia (low blood sugar) as a common side effect of Kalydeco. Additionally, hypertension (high blood pressure) has been noted as being associated with the use of medicines containing ivacaftor.

Q: Are there any common over-the-counter products that should be avoided with Kalydeco?

Regulatory labels specify that strong enzyme-inducing products, such as the herbal product St. John's Wort, is restricted from co-administration with Kalydeco. Furthermore, the consumption of grapefruit or Seville oranges and their juices is restricted from consumption while using the medicine.

Q: What is the effect of strong antibiotics on Kalydeco's effectiveness?

Official interaction statements indicate that strong CYP3A inhibitors, which includes certain antibiotics, can cause a substantial increase in ivacaftor exposure in the body. Conversely, strong CYP3A inducers (such as the antibiotic rifampin) can substantially decrease ivacaftor exposure, making the medicine less effective.

Q: Does Kalydeco cause weight changes or appetite changes?

Regulatory documents list loss of appetite as one of the symptoms documented as a symptom of potential liver problems. Research studies on Kalydeco have also observed that patients treated with the medicine may experience weight gain (measured by Body Mass Index).

Q: Is the R117H mutation one of the CFTR gene changes that responds to Kalydeco?

Yes, according to the official product indications, Kalydeco is approved for the treatment of cystic fibrosis in patients who have the R117H mutation in the CFTR gene. This mutation is known to be responsive to the medicine's action.

Q: What symptoms of liver issues should a person be aware of while on Kalydeco?

Official regulatory patient information specifies several signs of liver problems that regulatory information advises monitoring. These include symptoms like pain or discomfort in the upper right stomach area, yellowing of the skin or eyes, nausea or vomiting, loss of appetite, or dark, amber-colored urine.

Q: Have users reported experiencing side effects like 'brain fog' or difficulty concentrating?

While the official Kalydeco monotherapy label does not list 'brain fog' or difficulty concentrating, regulatory updates on related CFTR modulator medicines have noted infrequent reports of poor concentration and forgetfulness. Official sources currently indicate insufficient evidence to establish an increased risk specifically with Kalydeco monotherapy.

Q: What are examples of fat-containing foods that can be taken with Kalydeco?

Regulatory information requires Kalydeco to be administered with food containing fat to ensure proper absorption. Examples provided in patient information for the oral granules include mixing them with soft foods like yogurt, applesauce, or liquids such as milk or juice, provided they contain fat.

Q: Is it known whether using alcohol while on Kalydeco is safe?

Official regulatory documents, such as the prescribing information, do not contain a specific statement or recommendation about the safety of consuming alcohol while taking Kalydeco.

Kalydeco (ivacaftor) must be stored at room temperature, specifically between 68 mathrmF to 77 mathrmF (20 mathrmC to 25 mathrmC). The medication must be kept in its original container, tightly closed, and stored away from excess heat, moisture, and direct light. Keep the product from freezing.

The oral granules must remain in the foil packet until used. Once mixed with soft food or liquid, the preparation is stable for only one hour and must be consumed within this time; the mixed product must not be stored. Kalydeco, like all medicines, must be kept out of the sight and reach of children.

Do not keep outdated medicine or medicine no longer needed. Unused or expired Kalydeco must not be thrown away in household trash or down the drain, but should be disposed of as directed by a healthcare professional or local waste guidelines.